Synthetic Biology News Related News

Building Biotech on the Success of Semiconductors: an Interview with CustomArray CEO Brooke Anderson about GenScript’s Recent Acquisition

Anyone working in the cutting-edge field of synthetic biology is inevitably standing on the shoulders of giants. These are the shoulders of past biologists and, increasingly, the shoulders of computer scientists whose innovations are carrying biology to a new level. [...]

RebelBio launches a new biotech cohort in London

London, 16. January 2018 - RebelBio, a life sciences accelerator of SOSV, the accelerator VC, launches its latest cohort in London. We're in the middle of the genomic revolution and the RebelBio accelerator has just launched a new cohort in London [...]

By | January 17th, 2018|Bioentrepreneurship, Synthetic Biology News|

Estimation of a 69 % reduction in greenhouse gases emissions for fully renewable ETBE compared to fossil gasoline

Evry (France) – 15 January 2018 – Global Bioenergies (Euronext Growth: ALGBE) has entrusted EVEA, a company specialized in calculation of Life Cycle Assessment (LCA), with a study focused on the products to be manufactured in the future IBN-One plant. Fully renewable [...]

Manus Bio awarded funding to develop novel production method for Artemisinin

CAMBRIDGE, Mass., Jan. 11, 2018 - Manus Bio Inc. (Manus Bio), a company which produces complex natural products through advanced fermentation, announced today that it has received funding from the Bill & Melinda Gates Foundation for the development of a [...]

Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

January 09, 2018 Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches Engages the Parker Institute’s extensive immunotherapy expertise and academic and research network on studies that have the potential [...]

AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock

Wednesday, January 10, 2018 6:00 am EST - SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a public offering of 4,000,000 [...]